Registration Number
2125U011031, Article
popup.category
Стаття
Title
popup.author
Zlahoda V.
Bobrytska L.
Nazarova O.
Tarasenko V.
Shpychak O.
Nazarkina V.
Hrytsenko V.
popup.publication
16-11-2025
popup.source_user
Вінницький національний медичний університет ім. М. І. Пирогова
popup.source
https://dspace.vnmu.edu.ua/123456789/10471
popup.publisher
ScienceRise: Pharmaceutical Science
Description
The aim: development of the composition and technology of a medicinal drug in the form of capsules with a dry extract of Rauwolfia for the treatment of hypertension. Materials and methods. Experimental samples of masses for encapsulation contained 2.0 mg of dry Rauwolfia extract and various excipients used in the technology of solid dosage forms. The study of pharmaco-technological characteristics was carried out on the devices of the company “Pharma Test” (Germany). The time of decay was determined on the device of the company “Erweka” (Germany). A comparative analysis of the cost calculation of the production of tablets and capsules with dry rauwolfia extract was carried out by the “cost plus” method. Results. The use of PROSOLV® SMCC HD 90 improved the flowability, homogeneity and homogeneity of the mass with Rauwolfia dry extract powder, considering the low dosage of the substance of 2 mg. It has been experimentally proven that PROSOLV® SMCC HD 90 shortens the disintegration time as a disintegrant, because due to silicate moisture easily penetrates into the MCCC, hydrophilic bridges are formed, wettability increases and mass swelling occurs. The multifunctionality of PROSOLV® SMCC HD 90 three-in-one excipient, which has the properties of a filler, a disintegrant and a glidant, makes it easy to apply direct encapsulation technology, replace and reduce the number of excipients and thus increase production efficiency. Conclusions. When developing the composition of capsules with dry rauwolfia extract, the effect of various excipients on the pharmaco-technological properties of encapsulating masses and ready-made capsules was investigated. The combined excipient, namely PROSOLV® SMCC HD 90, having the properties of a filler, a disintegrant and a lubricant, in direct encapsulation technology is more effective in influencing the fluidity of the mass and disintegration of the capsules. The introduction of the direct encapsulation method will allow to expand the range of new medicines and improve existing technologies, in particular in the form of tablets, which are widely produced in industrial production. it is possible to attach specifically to Rauwolfia.
popup.nrat_date
2026-09-29
